Top-Rated Biotech Stocks

Recs

2

It's typically feast or famine when it comes to biotech stocks, but one big winner can more than make up for a bunch of losers. The secret is finding well-run companies delivering high-quality drugs before the market finds them.

Of course, that's easier said than done, and some biotech companies are already beyond their high-growth stage. Nevertheless, in that spirit, we'll use the aggregate intelligence of the 105,000-plus investors participating in Motley Fool CAPS to find biotech stocks that the community likes -- those with four- and five-star ratings. The community's approval could be a sign that further research is in order.

Here are five such stocks:

Company

Market Cap

% CAPS All-Star Bulls

CAPS Rating
(Out of 5)

CAPS Research

Amgen (Nasdaq: AMGN)

$46.8 B

94.3%

****

AMGN

Genentech (NYSE: DNA)

$77.7 B

96.3%

****

DNA

Genzyme (Nasdaq: GENZ)

$17.4 B

95.1%

*****

GENZ

ViroPharma (Nasdaq: VPHM)

$697 M

98.3%

*****

VPHM

Gilead Sciences (Nasdaq: GILD)

$49.0 B

97.6%

*****

GILD

Source: Motley Fool CAPS, as of June 11, 2008.

Come and join us on CAPS to learn more about these and countless other interesting stock ideas. Sign up for free.

Closed for 15 months – opening 10 days only! Get notified ahead of time as our expert portfolio manager invests $1 MILLION in the best opportunities from across The Motley Fool’s premium investment services. This is the first open since August 2008, by invitation only. Enter email below.

Disclosure is important to us here at The Motley Fool. The stocks mentioned in this article received their CAPS star ratings from participants in The Motley Fool's CAPS service. No individual person selected the stocks in this article, so there is no author to disclose an interest in them. Since this article was automatically generated by identifying the stocks rated by the CAPS community and by buyers in today's market, it is possible that Motley Fool personnel (and even The Motley Fool itself, through our Million Dollar Portfolio), have positions in these stocks. We thought you'd like to know that. You can learn more about The Motley Fool's disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 663351, ~/Articles/ArticleHandler.aspx, 11/10/2009 2:57:15 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Health-Care Reform: A Tale of Two Chambers

Related Tickers

3/26/2009 4:00 PM
DNA $94.97 Down +0.00 +0.00%
Genentech, Inc. CAPS Rating: ****
AMGN $54.91 Up +0.22 +0.40%
Amgen, Inc. CAPS Rating: ****
GENZ $52.54 Up +0.26 +0.50%
Genzyme Corp CAPS Rating: ****
GILD $46.58 Up +0.32 +0.69%
Gilead Sciences, I… CAPS Rating: *****
VPHM $7.60 Down -0.06 -0.78%
ViroPharma, Inc. CAPS Rating: *****

Community: Investing Wiki

Term Of The Hour

Enterprise value: Enterprise value is the value of a company, incorporating equity, debt, and cash. It is essentially a way of measuring what it would cost to buy the company. Also often called total enterprise value (TEV).

Want to learn more or edit this definition?
Click here to read more!